modelS01AA29
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Dibekacin | |
| ATC code: | S01AA29 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.26 | L |
| clearance: | 100 | ml/min |
| other parameters in model implementation | ||
Dibekacin is a semisynthetic aminoglycoside antibiotic, structurally related to kanamycin and amikacin. It has been used for the treatment of severe infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa and other resistant organisms. Dibekacin is generally administered via injection. It is not approved or available in many countries today due to the availability of newer, less nephrotoxic aminoglycosides.
Pharmacokinetics
Pharmacokinetic parameters are generally estimated from intravenous administration in adult patients with normal renal function. Specific published PK studies in humans are very limited, so these parameters are estimated based on the general aminoglycoside class and a few old studies referenced in reviews.
References
Lakota, EA, et al., & Rubino, CM (2019). Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution. Antimicrobial agents and chemotherapy 63(8) –. DOI:10.1128/AAC.00267-19 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31182524
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)